Developing In Vitro Diagnostics for Commercialization and Clinical Implementation by Wang, Ping
Academic Entrepreneurship for Medical
and Health Scientists
Volume 1
Issue 3 Intellectual Property-Regulatory Article 15
9-27-2019
Developing In Vitro Diagnostics for
Commercialization and Clinical Implementation
Ping Wang
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/ace/vol1/iss3/15
For more information, please contact repository@pobox.upenn.edu.
Developing In Vitro Diagnostics for Commercialization and Clinical
Implementation
Summary
• Even though in vitro diagnostics (IVDs) account for only 3% of healthcare spending, they generate
results that drive 70% of healthcare decisions by providing vital insights into patient health.
• Development and implementation of IVDs should provide value not only within the diagnostic lab but
also downstream in the clinical care pathway, by improving clinical outcomes and decreasing costs.
• This can be achieved by developing assays for new clinical biomarkers and/or with new analytical
technologies that address unmet clinical needs.
• Academic entrepreneurs can either serve as technology inventors or subject matter experts and partner
with major IVD companies to develop assays or platforms, or partner with startup companies to secure
grants/venture capital funding to support the development, clinical validation, and regulatory approval
of the inventions.
• Following regulatory approval, effective clinical implementation and adoption requires analytical
performance and user experience suitable for clinical needs, reasonable placement of the technology
within the clinical care pathway, effective user engagement and support, and positive health economics.
There are opportunities for academics to engage and contribute to all of the above aspects.
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Topic Relevance by Timeline 
Summary 
● Even though in vitro diagnostics (IVDs) account for only 3% of healthcare spending, they 
generate results that drive 70% of healthcare decisions by providing vital insights into 
patient health. 
● Development and implementation of IVDs should provide value not only within the diag-
nostic lab but also downstream in the clinical care pathway, by improving clinical 
outcomes and decreasing costs. 
● This can be achieved by developing assays for new clinical biomarkers and/or with new 
analytical technologies that address unmet clinical needs. 
● Academic entrepreneurs can either serve as technology inventors or subject matter experts 
and partner with major IVD companies to develop assays or platforms, or partner with 
startup companies to secure grants/venture capital funding to support the development, 
clinical validation, and regulatory approval of the inventions. 
● Following regulatory approval, effective clinical implementation and adoption requires an-
alytical performance and user experience suitable for clinical needs, reasonable placement 
of the technology within the clinical care pathway, effective user engagement and support, 
and positive health economics. There are opportunities for academics to engage and 
contribute to all of the above aspects. 
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Introduction 
In vitro diagnostics (IVDs) include assays and/or devices used to test human tissues or body fluids 
outside of the body, and to generate results for clinical decision-making in disease prevention, 
diagnosis, prognosis, or treatment. Although IVD testing costs account for only ~3% of healthcare 
spending, the results drive ~70% of healthcare decisions, thereby offering a lot of value down-
stream in the care pathway (Rohr et al.). The development of novel IVDs should follow the same 
principle, with the goal of generating value not only in diagnostic testing itself but also in the 
downstream care pathway (The Lewin Group, Inc.). Tests for new clinical biomarkers or with new 
analytical technologies are developed to allow more rapid, more sensitive, and more specific 
diagnosis of diseases, as well as higher efficiency in care coordination, which leads to improved 
patient outcomes and lower care costs. These are the driving forces behind IVD development, with 
a market compound annual growth rate estimated at 5.2%, to reach a market value of $87.93 billion 
by 2023 (ReportsnReports). Growth is driven by an increase in chronic diseases, emerging infec-
tious diseases, precision medicine, automation, point-of-care testing, and emerging economies 
(Glorikian). 
Regulation 
The development and clinical practice of IVDs are governed by two main regulatory agencies in 
the United States. IVD developers submit applications to the Food and Drug Administration (FDA) 
for either PMA or 510(K) approval to market their products as medical devices (see the chapter 
“FDA Device Regulation: 510(k), PMA”). The FDA categorizes each device as waived, moder-
ately complex, or highly complex, depending on the complexity level, including: knowledge to 
perform; training and experience required; reagents and materials preparation; characteristics of 
operational steps; calibration, quality control, proficiency testing materials; system 
troubleshooting and maintenance; and results interpretation and judgment. The supervising and 
performing personnel requirements and the quality control and validation requirements differ 
among these categories. Laboratory and personnel accreditation, certification, compliance, and 
reimbursement fall under the Centers for Medicare and Medicaid Services (CMS), which uses the 
Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations as the federal stand-
ards for all clinical laboratories. The Centers for Disease Control and Prevention (CDC) also 
supports clinical laboratory testing by providing scientific and technical advice and resources. 
Developing IVDs for Commercialization 
IVDs may be used in several different settings (CLIA-certified clinical laboratories, physician of-
fices, pharmacies, or homes). At this time, clinical implementation of novel IVDs may occur 
through two pathways: lab-developed tests (LDTs) or FDA-approved tests. The LDT pathway 
limits the practice of the test to the clinical laboratory that develops it. The FDA has historically 
exercised enforcement discretion on LDTs, but has indicated in recent years its intent to regulate 
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this category. Since the regulatory outlook of LDTs is not well defined at this stage, the rest of the 
chapter focuses on the pathway with the goal of FDA approval and wide clinical implementation.  
 
There are many different ways academic entrepreneurs may lead or participate in IVD develop-
ment. In one scenario, the academic entrepreneur may license a novel biomarker and/or associated 
assay, or license an assay platform from the research lab to a major IVD company for 
commercialization. The chemistry and engineering expertise of the IVD company may be 
leveraged to further develop the assay into formats more suitable for high-throughput testing, in 
order to achieve maximal distribution and impact. The medical affairs resources of an IVD com-
pany may also be leveraged to further demonstrate the clinical performance of the biomarker assay 
in disease detection or prognosis—comparable or superior to existing biomarker assays—in large 
patient populations. The IVD company takes the product through final regulatory approval. In 
another variation, the academic clinician may contribute clinical expertise and resources to clinical 
validation of the assay, which may be crucial for IVD companies to submit for regulatory agency 
approval, or for startup companies to obtain funding for further commercial development. 
 
In the second scenario, the academic entrepreneur developing the technology may choose to spin 
off a company to take the technology further down the commercialization path (see the chapter 
“Intellectual Property: Commercializing in a University Setting”). In the early phase of the tech-
nology development, the academic entrepreneur may try to obtain grant funding to support the 
development. Some of the funding sources may include Small Business Innovation Research 
(SBIR), Small Business Technology Transfer (STTR), and R01 grants from the National Institutes 
of Health (NIH), the National Science Foundation (NSF), the Centers for Disease Control and 
Prevention (CDC), the Department of Defense (DOD), and the Defense Advanced Research Pro-
jects Agency (DARPA) (see the chapters “SBIR/STTR Grants: Application Guidance”). A clearly 
targeted clinical application with well-defined clinical needs, technology gap, and target popula-
tion is crucial for the success of the grant applications, as well as for the eventual success of 
commercialization and clinical adoption. For this reason, the academic entrepreneur should engage 
and include team members with clinical and diagnostic expertise early in the technology 
development process (see the chapter “Building a Successful Startup Team”). Funding agencies 
also have various programs—e.g., I-Corps (see the chapter “I-Corps as a Training Tool for New 
Technology Development”), the Technology Niche Analyses Program, the Commercialization 
Accelerator Program, and the Concept to Clinic: Commercializing Innovation Program—that offer 
the grant awardees help in commercialization. Assistance offered through these programs may 
include market and customer discovery, product development mentoring, business strategy and 
outcomes, regulatory and reimbursement strategies, pitch coaching and networking, etc (see the 
chapters “Resources at Academic Entrepreneurship Centers” and “Reimbursement Strategies and 
CPT Codes for Device Development”). These programs are targeted to academic teams/companies 
at specific development phases, so it is critical to select the appropriate programs, as they typically 
require an intensive time investment. Simultaneously with or subsequent to grant funding, the 
academic entrepreneur may try to obtain venture capital funding or industry contracts to support 
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the technology development, clinical validation, and regulatory approval, and to grow the value of 
the company (see the chapters “Accelerators and Incubators”, “Angel Investors” and “Seeking 
Venture Capital Investment”). 
Clinical Implementation of IVDs 
Regulatory approval does not guarantee impactful clinical implementation and adoption. Several 
hurdles may prevent novel IVDs from being widely adopted. These include lack of exact match 
between technology and clinical needs lack of understanding in current and envisioned clinical 
care pathways; no demonstrated clinical utility and user-ability; suboptimal user experience, 
engagement, and support; and negative health economics. A lack of supporting health infrastruc-
ture may also prevent impactful implementation. In order to overcome these hurdles, the 
technology development team/company needs to conduct a clinical needs assessment and a care 
pathway analysis early on, and engage academic and clinical stakeholders throughout the process. 
The stakeholders are described in the next section. As an example, the development pathway for 
novel point-of-care technologies, from clinical needs assessment to clinical implementation, is 
presented in Wang and Kricka (Wang and Kricka).  
Obtaining Expert Counsel  
There are several important stakeholders in the development process of IVDs, besides the technol-
ogy developer. These include clinicians, clinical laboratorians, health economists, patients, service 
providers, and payers. In order to achieve maximal adoption and impact of the IVD technology, 
counsel from these stakeholders should be obtained. An academic environment can provide access 
to a large pool of candidate stakeholders, but it is important for the academic entrepreneur to also 
reach outside their institute and engage with other organizations, using nondisclosure agreements 
as needed to protect potential intellectual property (IP). In addition, an academic institution will 
likely have a technology transfer office that can assist with this process (see the chapter “Working 
with the University Technology Transfer Office”). Subject matter experts and other stakeholders 
may also be engaged through ad hoc interviewing or a scientific advisory board. The contract terms 
and costs will vary depending upon the level of engagement.  
 
A sample checklist with questions for different stakeholders during point-of-care technology 
development, optimization, and clinical adoption is summarized in Wang and Kricka (Wang and 
Kricka). Refer to Figure 1 and Table 4 for the pathway and checklist questions for point-of-care 
diagnostics development and clinical implementation (Wang and Kricka). Most aspects can be 
extrapolated to other types of IVDs.  
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Conclusion 
There are multiple ways academic entrepreneurs or clinicians can lead or participate in the devel-
opment, commercialization, and clinical implementation of IVDs. Contributions may be made in 
clinical needs assessment, technology development, clinical validation, commercialization, and 
implementation.  
Resources 
1. FDA CLIA database of approved IVD assays and devices: 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/search.cfm. 
2. Centers for Disease Control and Prevention (CDC) website on CLIA, law and 
regulations, documents, test complexity, CLIA laboratory database search, and test 
reference materials: https://wwwn.cdc.gov/CLIA/Default.aspx. 
3. FDA website on IVDs, including information on LDTs: 
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics
/default.htm. 
4. American Association of Clinical Chemistry (AACC) website:  
https://www.aacc.org/. The website also has information about annual scientific programs 
meetings and expositions. These provide up-to-date educational, clinical, regulatory, and 
industry insights into clinical laboratory science and the IVD industry. 
5. International Federation of Clinical Chemistry and Laboratory Medicine website: 
http://www.ifcc.org/. This organization expands the global reach of the vision and 
practice of laboratory medicine and IVD. The website includes information about 
relevant conferences and congresses. 
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